Related Experiment Videos
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas
Abstract:
DTIC was one of the first of several new agents evaluated by the Southwest Oncology Group (SWOG) and the M.D. Anderson Hospital and Tumor Institute (MDAH) in the therapy of adult patients with metastatic sarcomas. It yielded an overall response rate of 17%. This is similar to that seen in a review of 138 patients who represent the total number reported in either published or unpublished data. The subsequent addition of DTIC to adriamycin in several studies carried out at the MDAH and in the SWOG has increased the complete and partial remission rate over that seen with adriamycin alone, and more importantly has increased remission duration and survival. DTIC is currently used in combination with adriamycin in the first-line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.
Insights
Dacarbazine (DTIC) showed a 17% response rate in metastatic sarcomas. Combining DTIC with adriamycin improved remission rates, duration, and survival in adult sarcoma patients.
Area of Science:
- Oncology
- Medical Oncology
- Pharmacology
Background:
- Metastatic sarcomas are aggressive cancers with limited treatment options.
- Dacarbazine (DTIC) was an early agent evaluated for advanced sarcomas.
- Adriamycin is a standard chemotherapeutic agent for sarcomas.
Purpose of the Study:
- To evaluate the efficacy of Dacarbazine (DTIC) as a single agent in metastatic sarcomas.
- To assess the impact of adding DTIC to adriamycin therapy in sarcoma patients.
- To determine if combination therapy improves remission rates, duration, and survival.
Main Methods:
- Clinical trials conducted by the Southwest Oncology Group (SWOG) and M.D. Anderson Hospital and Tumor Institute (MDAH).
- Evaluation of DTIC as monotherapy.
- Assessment of DTIC in combination with adriamycin.
- Review of published and unpublished data on 138 patients.
Main Results:
- DTIC monotherapy yielded an overall response rate of 17% in adult metastatic sarcomas.
- Combination therapy with DTIC and adriamycin increased complete and partial remission rates compared to adriamycin alone.
- The addition of DTIC significantly improved remission duration and patient survival.
Conclusions:
- DTIC is an effective agent in the treatment of metastatic sarcomas.
- Combination therapy with DTIC and adriamycin is superior to adriamycin monotherapy for metastatic sarcomas.
- DTIC should be considered in first-line therapy and for patients with relapsed disease not previously treated with DTIC.